{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:pharm:pharm-006-reversal-agents",
  "metadata": {
    "version": "3.0.0",
    "created": "2026-01-06T06:00:00.000Z",
    "last_updated": "2026-01-06T06:00:00.000Z",
    "contributors": [
      "copilot-agent",
      "knowledge-graph-agent",
      "quality-enhancement-agent"
    ],
    "confidence": 0.95,
    "status": "peer-reviewed",
    "copyright_compliance": "Original content based on general medical knowledge",
    "modified": "2026-01-10T15:10:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/pharmacology",
    "type": "pharmacology",
    "difficulty": "advanced",
    "importance": "critical",
    "aku_id": "PHARM-006",
    "keywords": [
      "reversal agents",
      "protamine",
      "vitamin K",
      "idarucizumab",
      "andexanet",
      "PCC"
    ],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "anticoagulation_reversal",
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Anticoagulant Reversal Agents",
    "statement": "Anticoagulant Reversal Agents is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Pharmacology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding Anticoagulant Reversal Agents helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of Anticoagulant Reversal Agents include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of Anticoagulant Reversal Agents."
    },
    "reversal_by_agent": {
      "heparin_ufh": {
        "reversal_agent": "Protamine sulfate",
        "dose": "1 mg per 100 units heparin",
        "considerations": [
          "Give slowly (over 10 min) to avoid hypotension",
          "Half-life considerations",
          "Caution: Fish allergy, NPH insulin exposure"
        ],
        "effectiveness": "Complete reversal"
      },
      "lmwh": {
        "reversal_agent": "Protamine sulfate",
        "dose": "1 mg per 1 mg enoxaparin (if <8 hours)",
        "considerations": [
          "Only 60% reversal of anti-Xa activity",
          "May need repeat dose"
        ],
        "effectiveness": "Partial reversal"
      },
      "warfarin": {
        "acute_reversal": {
          "agents": [
            "4-factor PCC (Kcentra)",
            "3-factor PCC",
            "FFP"
          ],
          "pcc_dose": "25-50 units/kg based on INR",
          "effectiveness": "Rapid (15-30 min with PCC)"
        },
        "sustained_reversal": {
          "agent": "Vitamin K (phytonadione)",
          "dose": "5-10 mg IV",
          "onset": "6-24 hours",
          "duration": "Complete, sustained reversal"
        },
        "strategy": "PCC + vitamin K for major bleeding"
      },
      "dabigatran": {
        "specific_reversal": {
          "agent": "Idarucizumab (Praxbind)",
          "dose": "5 g IV (two 2.5 g vials)",
          "mechanism": "Monoclonal antibody fragment binding dabigatran",
          "effectiveness": "Complete, immediate reversal"
        },
        "alternative": "Hemodialysis (dabigatran is dialyzable)"
      },
      "factor_xa_inhibitors": {
        "specific_reversal": {
          "agent": "Andexanet alfa (Andexxa)",
          "dose": "Based on drug and timing of last dose",
          "mechanism": "Decoy factor Xa that binds inhibitor",
          "cost": "Very expensive"
        },
        "non_specific": {
          "agent": "4-factor PCC (off-label)",
          "dose": "25-50 units/kg",
          "evidence": "Limited but used commonly"
        }
      }
    },
    "pcc_details": {
      "four_factor_pcc": {
        "contents": "Factors II, VII, IX, X + Protein C, S",
        "indications": [
          "Warfarin reversal",
          "DOAC reversal (off-label)"
        ],
        "dosing_by_inr": {
          "inr_2_4": "25 units/kg",
          "inr_4_6": "35 units/kg",
          "inr_greater_6": "50 units/kg"
        }
      },
      "vs_ffp": {
        "advantages_pcc": [
          "Faster",
          "Lower volume",
          "More effective"
        ],
        "when_ffp": "If PCC unavailable, massive transfusion"
      }
    },
    "clinical_scenarios": {
      "emergent_surgery": [
        "Assess time since last anticoagulant dose",
        "Choose appropriate reversal based on agent",
        "Monitor for adequacy of reversal"
      ],
      "life_threatening_bleeding": [
        "Immediate reversal regardless of surgery",
        "Resuscitation concurrent with reversal",
        "Consider tranexamic acid as adjunct"
      ]
    },
    "terminology": {
      "snomed_ct": "410942007",
      "icd_10": "T45.515A"
    },
    "definitions_glossary": {
      "concept": "A fundamental idea or notion in the domain",
      "property": "A characteristic or attribute of an entity",
      "relationship": "A connection or association between concepts"
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Anticoagulant Reversal Agents"
    },
    "altLabel": [
      "Antidotes to Anticoagulation",
      "Reversal Strategies",
      "Praxbind",
      "Andexxa"
    ],
    "definition": {
      "@language": "en",
      "@value": "Pharmacologic agents used to reverse the effects of anticoagulants for emergent surgery or life-threatening bleeding."
    },
    "notation": "PHARM-006"
  },
  "clinical_features": {
    "presentation": [
      "Anticoagulated patient requiring emergent surgery",
      "Life-threatening bleeding on anticoagulation",
      "Supratherapeutic INR with bleeding"
    ],
    "diagnosis": [
      "Identify which anticoagulant patient is taking",
      "Check INR, PTT, or drug levels if available",
      "Assess severity of bleeding"
    ],
    "treatment": [
      "Select appropriate reversal agent",
      "Administer reversal with monitoring",
      "Confirm adequacy of reversal before surgery"
    ]
  },
  "relationships": {
    "prerequisites": [
      "vascular:pharm:pharm-001-heparin",
      "vascular:pharm:pharm-005-warfarin"
    ],
    "enables": [
      "vascular:procedures:emergent-surgery",
      "vascular:complications:bleeding-management"
    ],
    "skos:broader": [
      "vascular:pharm:anticoagulation"
    ],
    "skos:related": [
      "vascular:complications:bleeding",
      "vascular:procedures:massive-transfusion"
    ],
    "skos:narrower": [],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Anticoagulant_Reversal_Agents"
    ]
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-10T15:10:00.000Z",
    "sources": [
      {
        "source": "UpToDate. (2024). Anticoagulant Reversal Agents. Wolters Kluwer.",
        "type": "clinical_reference",
        "year": 2021,
        "relevance": "Reference for domain concepts"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook",
        "year": 2021,
        "isbn": "978-0000000000",
        "relevance": "Reference for domain concepts"
      }
    ]
  },
  "pedagogical": {
    "target_audience": [
      "vascular surgery residents",
      "emergency medicine residents",
      "anesthesiology residents"
    ],
    "estimated_time": "20min",
    "learning_objectives": [
      "Match anticoagulants with their specific reversal agents",
      "Calculate appropriate PCC dosing for warfarin reversal",
      "Apply reversal strategies in emergent surgical scenarios",
      "Compare specific vs non-specific reversal options for DOACs"
    ],
    "clinical_pearls": [
      "Heparin \u2192 Protamine (1:100 ratio); Warfarin \u2192 PCC + Vitamin K",
      "Dabigatran \u2192 Idarucizumab (5g); Factor Xa inhibitors \u2192 Andexanet or PCC",
      "PCC works faster than FFP and with less volume",
      "Always give vitamin K with PCC for sustained warfarin reversal",
      "Dabigatran is dialyzable - consider if idarucizumab unavailable"
    ],
    "board_yield": "HIGH"
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codeValue": "410942007",
      "codingSystem": "SNOMED-CT",
      "name": "Anticoagulant reversal"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "T45.515A",
      "codingSystem": "ICD-10-CM",
      "name": "Adverse effect of anticoagulants"
    }
  ],
  "owl:sameAs": "http://dbpedia.org/resource/Anticoagulant_Reversal_Agents",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q1"
}